AngioDynamics officer plans $290K share sale
The notice lists Morgan Stanley Smith Barney LLC as broker and Nasdaq as the exchange for the proposed sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AngioDynamics, Inc. officer Stephen Trowbridge reported a proposed sale of 23,615 common shares, with an aggregate market value of $289,722 and an approximate sale date of October 29, 2026. Morgan Stanley Smith Barney LLC is listed as broker, and Nasdaq as the exchange.
The shares to be sold include shares acquired as restricted stock, through the Employee Stock Purchase Plan, and as performance shares. A separate prior-sales entry records 1,720 common shares sold October 28, 2026, for $20,929.09 in gross proceeds.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock financial
Employee Stock Purchase Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.